Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) released its earnings results on Monday. The company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.91) by $0.60, FiscalAI reports.
Cadrenal Therapeutics Price Performance
CVKD stock traded up $0.03 during trading on Tuesday, reaching $1.43. 13,683 shares of the stock traded hands, compared to its average volume of 183,494. The firm has a market capitalization of $5.09 million, a PE ratio of -0.29 and a beta of 1.94. The business’s 50 day moving average price is $1.09 and its 200-day moving average price is $3.61. Cadrenal Therapeutics has a 52-week low of $0.82 and a 52-week high of $12.50.
Analyst Ratings Changes
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cadrenal Therapeutics in a report on Thursday, October 15th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $13.00.
Get Our Latest Research Report on Cadrenal Therapeutics
About Cadrenal Therapeutics
Cadrenal Therapeutics is a clinical-stage biopharmaceutical company developing treatments to prevent blood clots in people with cardiovascular conditions that require long-term anticoagulation. Its pipeline centers on tecarfarin, an investigational oral anticoagulant being developed as a potential alternative to warfarin. Tecarfarin is designed to be processed through a different metabolic pathway than warfarin and is being studied for patients with needs such as mechanical heart valves and end-stage renal disease.
Read More
- Five stocks we like better than Cadrenal Therapeutics
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
- Tyson Foods’ 10% Surge Puts a Breakout in Sight, But Wall Street Remains Cautious
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
Receive News & Ratings for Cadrenal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cadrenal Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
